Kennedy Capital Management LLC Buys 20,009 Shares of LivaNova PLC $LIVN

Kennedy Capital Management LLC increased its stake in LivaNova PLC (NASDAQ:LIVN) by 8.9% during the fourth quarter, HoldingsChannel reports. The firm owned 245,732 shares of the company’s stock after acquiring an additional 20,009 shares during the period. Kennedy Capital Management LLC’s holdings in LivaNova were worth $15,120,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of LIVN. Artisan Partners Limited Partnership raised its holdings in shares of LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after purchasing an additional 1,179,436 shares during the period. Wellington Management Group LLP raised its holdings in LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after acquiring an additional 1,067,349 shares during the period. Invesco Ltd. raised its holdings in LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after acquiring an additional 902,447 shares during the period. Scopia Capital Management LP bought a new stake in LivaNova during the 2nd quarter valued at $36,657,000. Finally, Millennium Management LLC raised its holdings in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after acquiring an additional 544,033 shares during the period. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

LIVN has been the topic of a number of analyst reports. Barclays boosted their target price on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Piper Sandler reissued an “overweight” rating and set a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Needham & Company LLC boosted their target price on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Robert W. Baird lowered their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, LivaNova currently has an average rating of “Moderate Buy” and an average price target of $79.38.

LivaNova Price Performance

LIVN opened at $79.39 on Monday. LivaNova PLC has a one year low of $41.01 and a one year high of $80.74. The company has a fifty day moving average price of $69.08 and a 200-day moving average price of $65.81. The firm has a market capitalization of $4.36 billion, a P/E ratio of 40.71 and a beta of 0.88. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same period in the previous year, the business earned $0.88 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities research analysts expect that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.